Success Story: NIW Victory for A Biostatistician! Approved with Premium Processing and Our Strategic Support
Client’s Testimonial:
“NAILG’s attorney team has been communicative and professional. They always provide on-time feedback and further instructions. This makes the application process clear and straightforward. Highly recommended.”
On March 9th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Biostatistician I in the Field of Biostatistics (Approval Notice).
General Field: Biostatistics
Position at the Time of Case Filing: Biostatistician I
Country of Origin: Taiwan
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: March 9th, 2025
Processing Time: 1 month, 20 days (Premium Processing Requested)
Case Summary:
We are pleased to share the successful approval of an I-140 NIW (National Interest Waiver) petition for a skilled professional in the field of biostatistics. This rapid adjudication reflects the exceptional value and national importance of the petitioner’s work, which centers on enhancing the design and analysis of clinical trials through advanced statistical methodologies and machine learning.
With an MS degree in biostatistics and a background in public health, the petitioner has contributed to critical research aimed at improving drug development for oncology, cardiovascular diseases, and infectious diseases. His proposed endeavor focuses on creating innovative tools that optimize clinical trial accuracy, accelerate therapeutic approvals, and ultimately improve public health outcomes in the U.S. and globally.
Currently employed as a biostatistician, the petitioner supports ongoing clinical studies by designing and implementing statistical analysis plans, particularly for phase I/II trials. His work ensures regulatory compliance and addresses pressing challenges in evaluating treatment-emergent safety, especially in complex conditions such as heart disease and cancer.
In support of his EB-2 NIW petition, we documented:
● 3 peer-reviewed journal articles,
● 5 conference abstracts, including 1 first-authored,
● A total of 38 citations, reflecting his influence in the research community,
● Multiple papers ranked among the top 10–20% most cited in clinical medicine for their publication years.
The significance of his research is further underscored by notable funding from prestigious institutions, including the National Institutes of Health, the National Heart, Lung, and Blood Institute, the National Cancer Institute, and the American Heart Association. This level of support highlights the national impact and trust placed in the petitioner’s methodologies.To bolster his petition, 2 recommendation letters from field experts were submitted, including one from an independent source. These letters attest to the originality and practical application of his work across multiple high-need therapeutic areas.
“[Client] has and continues to contribute valuable research to understand the psychological strain placed on healthcare workers during public health crises. This speaks to his sustained leadership in biostatistics research and warrants the continuation of his work.”
We are honored to have supported this client's NIW journey through NAILG. His continued contributions to clinical trial science promise to shape the next generation of life-saving therapies with greater precision and speed, further strengthening public health infrastructure in the United States.